PHARMAZEUTISCHES PRAEPARAT MIT SYNERGISTISCHER ANALGETISCHER AKTIVITAET

1396663 Analgesics CHINOIN GYGYSZER ES VEGYESZETI TERMEKEK GYARA RT 2 Aug 1973 [3 Aug 1972 19 Dec 1972] 36873/73 Heading A5B Pharmaceutical compositions having synergistic analgesic activity comprise at least one azido compound of formula (I) or a pharmaceutically acceptable salt thereof such as the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SZLAVIK,LASZLO, NAGY,SANDOR, KNOLL,JOZSEF,DR, FUERST,ZSUZSANNA,DR, HERMECZ,ISTVAN, BOGNAR,REZSO,DR, MESZAROS,ZOLTAN,DR, SZEMMIKLOSI,PETER,DR, VALOVICS,GYULA, DAVID,AGOSTON,DR, MANDI,ATTILA, MAKLEIT,SANDOR,DR
Format: Patent
Sprache:ger
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:1396663 Analgesics CHINOIN GYGYSZER ES VEGYESZETI TERMEKEK GYARA RT 2 Aug 1973 [3 Aug 1972 19 Dec 1972] 36873/73 Heading A5B Pharmaceutical compositions having synergistic analgesic activity comprise at least one azido compound of formula (I) or a pharmaceutically acceptable salt thereof such as the bitartrate salt wherein R is hydrogen, methyl, ethyl, acetyl or morpholino-methyl in association with at least one compound selected from compounds of formula (II) wherein R1, R2 and R3 are hydrogen or C 1-6 alkyl and the dotted lines represent optionally hydrogenated bonds, and pharmaceutically acceptable salts and quaternary salts thereof such as a chloride, bromide, nitrate, sulphate, methylsulphate or ethylsulphate and analgesic butyrophenone derivatives, optionally in admixture with a pharmaceutically acceptable solid or liquid carrier or diluent. The compound of formula (I) may be azidomorphine, azidocodeine, azidoethylmorphine, azidoacetyl-morphine or azidomorpholinomethyl-morphine, the compound of formula (II) may be 1, 6-dimethyl-3-carbethoxy-4-oxo-6, 7, 8, 9-tetrahydro-homo-pyrimidazolium methosulphate and the butyrophenone derivative is preferably 4'- fluoro-4-[4-[2-oxo-2, 3-dihydrobenzimidazolyl- (1)]-1, 2, 3, 6-tetrahydropyridyl-(1)]-butyrophenone. The compositions may be administered orally or parenterally in the form of tablets, capsules, pills, coated pills, injectable preparations and powder ampoules.